Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Robot-assisted RVC with tPA for CRVO
NCT03417401Phase 1Withdrawn
- Sponsor
- UZ Leuven
- Start
- Oct 2018
- Primary completion
- Dec 2021
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tissue-plasminogen activator in central retinal vein occlusion (CRVO), sponsored by UZ Leuven. Primary endpoints: Success rate of retinal vein cannulation, Number of intervention-related surgical complications at 7 days and 2 more. Planned start Oct 2018; status: withdrawn.
02
Drugs
tissue-plasminogen activator
03
Conditions
central retinal vein occlusion (CRVO)
Beyond the preview
Go deeper on NCT03417401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03417401.